BR112022001793A2 - Método para tratar a doença de alzheimer inibindo-se a absorção de aminoácidos por células t - Google Patents
Método para tratar a doença de alzheimer inibindo-se a absorção de aminoácidos por células tInfo
- Publication number
- BR112022001793A2 BR112022001793A2 BR112022001793A BR112022001793A BR112022001793A2 BR 112022001793 A2 BR112022001793 A2 BR 112022001793A2 BR 112022001793 A BR112022001793 A BR 112022001793A BR 112022001793 A BR112022001793 A BR 112022001793A BR 112022001793 A2 BR112022001793 A2 BR 112022001793A2
- Authority
- BR
- Brazil
- Prior art keywords
- uptake
- inhibiting
- disease
- cells
- amino acids
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
método para tratar a doença de alzheimer inibindo-se a absorção de aminoácidos por células t. é fornecida o uso de um reagente para inibir a absorção de aminoácidos por células t virgens na preparação de um fármaco para tratar a doença de alzheimer em um sujeito.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910720450.0A CN112336859A (zh) | 2019-08-06 | 2019-08-06 | 通过抑制t细胞摄取氨基酸治疗阿尔茨海默病的方法 |
PCT/CN2020/107224 WO2021023238A1 (zh) | 2019-08-06 | 2020-08-05 | 通过抑制t细胞摄取氨基酸治疗阿尔茨海默病的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022001793A2 true BR112022001793A2 (pt) | 2022-03-22 |
Family
ID=74366428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022001793A BR112022001793A2 (pt) | 2019-08-06 | 2020-08-05 | Método para tratar a doença de alzheimer inibindo-se a absorção de aminoácidos por células t |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220273598A1 (pt) |
EP (1) | EP4011394A4 (pt) |
JP (1) | JP2022543015A (pt) |
KR (1) | KR20220044552A (pt) |
CN (2) | CN112336859A (pt) |
AU (1) | AU2020324210A1 (pt) |
BR (1) | BR112022001793A2 (pt) |
CA (1) | CA3148903A1 (pt) |
IL (1) | IL290095A (pt) |
MX (1) | MX2022001076A (pt) |
WO (1) | WO2021023238A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115808492A (zh) * | 2021-09-14 | 2023-03-17 | 中国科学院深圳先进技术研究院 | 一种阿尔兹海默症生物标志物天冬酰胺及其应用 |
CN115317480B (zh) * | 2022-09-01 | 2023-05-16 | 新乡医学院 | N-(3-甲基-5-异噻唑基)-2-氧代-3-(2h)-苯并噁唑乙酰胺的药物应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1160080C (zh) * | 2001-10-01 | 2004-08-04 | 青岛海洋大学 | 褐藻胶寡糖作为制备预防因东莨菪碱所致痴呆药物的应用 |
US7462459B2 (en) * | 2004-01-30 | 2008-12-09 | Xenoport, Inc. | LAT1 transporters expressed in blood brain barrier cells |
AU2012345732B2 (en) * | 2011-11-30 | 2016-07-14 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
GB201504432D0 (en) * | 2015-03-17 | 2015-04-29 | Electrophoretics Ltd | Materials and methods for diagnosis and treatment of alzheimers disease |
US20190059433A1 (en) * | 2017-08-24 | 2019-02-28 | Wisconsin Alumni Research Foundation | Compositions and methods for restoring metabolic health |
CN111491632A (zh) * | 2017-12-28 | 2020-08-04 | J制药股份有限公司 | 癌症治疗药 |
-
2019
- 2019-08-06 CN CN201910720450.0A patent/CN112336859A/zh active Pending
-
2020
- 2020-08-05 BR BR112022001793A patent/BR112022001793A2/pt unknown
- 2020-08-05 CA CA3148903A patent/CA3148903A1/en active Pending
- 2020-08-05 CN CN202080036533.9A patent/CN113874038A/zh active Pending
- 2020-08-05 EP EP20850618.8A patent/EP4011394A4/en active Pending
- 2020-08-05 AU AU2020324210A patent/AU2020324210A1/en not_active Abandoned
- 2020-08-05 MX MX2022001076A patent/MX2022001076A/es unknown
- 2020-08-05 WO PCT/CN2020/107224 patent/WO2021023238A1/zh unknown
- 2020-08-05 US US17/631,804 patent/US20220273598A1/en active Pending
- 2020-08-05 KR KR1020227007376A patent/KR20220044552A/ko not_active Application Discontinuation
- 2020-08-05 JP JP2022506312A patent/JP2022543015A/ja active Pending
-
2022
- 2022-01-24 IL IL290095A patent/IL290095A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020324210A1 (en) | 2022-03-10 |
EP4011394A4 (en) | 2023-07-19 |
WO2021023238A1 (zh) | 2021-02-11 |
CN113874038A (zh) | 2021-12-31 |
IL290095A (en) | 2022-03-01 |
CN112336859A (zh) | 2021-02-09 |
EP4011394A1 (en) | 2022-06-15 |
CA3148903A1 (en) | 2021-02-11 |
WO2021023238A9 (zh) | 2021-11-04 |
US20220273598A1 (en) | 2022-09-01 |
JP2022543015A (ja) | 2022-10-07 |
KR20220044552A (ko) | 2022-04-08 |
MX2022001076A (es) | 2022-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR106702A2 (es) | Uso de un anticuerpo antagonista anti-ngf para la preparación de un medicamento | |
ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
UY32691A (es) | Compuestos de 1h-imidazo-[4,5-c]-quinolinona | |
AR092818A1 (es) | Anticuerpo tau humanizado | |
CR20110608A (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
BR112022001793A2 (pt) | Método para tratar a doença de alzheimer inibindo-se a absorção de aminoácidos por células t | |
CR20150016A (es) | Anticuerpo monoclonal | |
AR092779A1 (es) | Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau | |
CO6382134A2 (es) | Sales y formas de cristal del 2-metil-2-[4-(metil-2-oxo-8-quinolin-3-3il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]propionitrilo | |
CL2013003146A1 (es) | Formulación estable que comprende anticuerpo anti alfa 4 beta 7 y al menos un aminoacido libre; metodo para preparar la formulación; uso para tratar enfermedad inflamatoria. | |
CR20110556A (es) | Proteinas de fusion rage y metodos de empleo | |
ECSP13012609A (es) | Composición farmacéutica | |
CL2008003197A1 (es) | Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer. | |
ECSP099833A (es) | Anticuerpos humanizados contra el globulomero a?(20-42) y sus usos | |
BR112019001536A2 (pt) | posicionamento de fechamento de força ou de fechamento de forma de moldes cirúrgicos para a odontologia de implante guiada | |
BR112015008143A2 (pt) | complexos, polipeptídeo e/ou polinucleotídeo isolado e purificado, composições, métodos para preparar, produzir ou obter complexos, para expandir e/ou desenvolver populações de células t autorreativas antipatogênicas e/ou para tratar esclerose múltipla ou distúrbio relacionado em sujeito com essa necessidade, kit e uso de complexos, de polipeptídeo e/ou de polinucleotídeo isolados e purificados e/ou de composições | |
BR112016018205A8 (pt) | métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente | |
EP3939606A3 (en) | Improved methods and compounds for eliminating immune responses to therapeutic agents | |
BR112013020265A2 (pt) | formas de rifaximina e uso das mesmas | |
CR10842A (es) | Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico por imagenes | |
BR112015017759A2 (pt) | inibidores de fosfolipase a2 associada à lipoproteína (lp-pla2) à base de 2,3-di-hidroimidazol[1,2-c]pirimidin-5(1h)-ona | |
BR112013019513A2 (pt) | métodos para o tratamento de úlceras diabéticas do pé | |
BRPI0913291A2 (pt) | composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto | |
BR112014001665A2 (pt) | compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz | |
AR109224A2 (es) | Formas de sales cristalinas de un compuesto 8-azabiciclo[3,2,1]octano, composición farmacéutica que las comprende, procesos para prepararlas, compuesto intermediario de síntesis relacionado y su uso para la fabricación de un medicamento |